Regular
NAV (05-Sep-24)
Returns (Since Inception)
Fund Size
₹1,168 Cr
Expense Ratio
2.25%
ISIN
INF789F01695
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
28 Jun 1999
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+56.86%
+54.79% (Cat Avg.)
3 Years
+18.78%
+18.09% (Cat Avg.)
5 Years
+29.11%
+29.12% (Cat Avg.)
10 Years
+13.60%
+15.75% (Cat Avg.)
Since Inception
+15.51%
— (Cat Avg.)
Equity | ₹1,138.29 Cr | 97.48% |
Debt | ₹1.26 Cr | 0.11% |
Others | ₹28.2 Cr | 2.41% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹133.94 Cr | 11.47% |
Cipla Ltd | Equity | ₹77.64 Cr | 6.65% |
Ajanta Pharma Ltd | Equity | ₹64.87 Cr | 5.56% |
Dr Reddy's Laboratories Ltd | Equity | ₹61.24 Cr | 5.24% |
Apollo Hospitals Enterprise Ltd | Equity | ₹44.89 Cr | 3.84% |
Glenmark Pharmaceuticals Ltd | Equity | ₹43.35 Cr | 3.71% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹41.33 Cr | 3.54% |
Aurobindo Pharma Ltd | Equity | ₹39.24 Cr | 3.36% |
Procter & Gamble Health Ltd | Equity | ₹38.61 Cr | 3.31% |
Fortis Healthcare Ltd | Equity | ₹35.01 Cr | 3.00% |
Suven Pharmaceuticals Ltd | Equity | ₹34.72 Cr | 2.97% |
Divi's Laboratories Ltd | Equity | ₹34.07 Cr | 2.92% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹33.17 Cr | 2.84% |
Torrent Pharmaceuticals Ltd | Equity | ₹31.37 Cr | 2.69% |
Gland Pharma Ltd | Equity | ₹30.18 Cr | 2.58% |
Net Current Assets | Cash | ₹28.14 Cr | 2.41% |
Zydus Lifesciences Ltd | Equity | ₹27.66 Cr | 2.37% |
Caplin Point Laboratories Ltd | Equity | ₹26.67 Cr | 2.28% |
Alkem Laboratories Ltd | Equity | ₹26.24 Cr | 2.25% |
Metropolis Healthcare Ltd | Equity | ₹24.45 Cr | 2.09% |
Pfizer Ltd | Equity | ₹23.05 Cr | 1.97% |
Emcure Pharmaceuticals Ltd | Equity | ₹21.86 Cr | 1.87% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹19.9 Cr | 1.70% |
Marksans Pharma Ltd | Equity | ₹19.16 Cr | 1.64% |
Jupiter Life Line Hospitals Ltd | Equity | ₹18.03 Cr | 1.54% |
Ipca Laboratories Ltd | Equity | ₹16.55 Cr | 1.42% |
Syngene International Ltd | Equity | ₹15.64 Cr | 1.34% |
Star Health and Allied Insurance Co Ltd | Equity | ₹15.48 Cr | 1.33% |
Sequent Scientific Ltd | Equity | ₹15.21 Cr | 1.30% |
Windlas Biotech Ltd | Equity | ₹14.18 Cr | 1.21% |
Vijaya Diagnostic Centre Ltd | Equity | ₹13.7 Cr | 1.17% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹13.58 Cr | 1.16% |
Orchid Pharma Ltd | Equity | ₹13.44 Cr | 1.15% |
Poly Medicure Ltd | Equity | ₹13.24 Cr | 1.13% |
Concord Biotech Ltd | Equity | ₹12.96 Cr | 1.11% |
Alembic Pharmaceuticals Ltd | Equity | ₹12.76 Cr | 1.09% |
Ami Organics Ltd | Equity | ₹12.43 Cr | 1.06% |
Indegene Ltd | Equity | ₹10.63 Cr | 0.91% |
Rainbow Childrens Medicare Ltd | Equity | ₹7.84 Cr | 0.67% |
India (Republic of) | Bond - Short-term Government Bills | ₹1.26 Cr | 0.11% |
Clearing Corporation Of India Ltd. Std Margin | Cash - Repurchase Agreement | ₹0.06 Cr | 0.01% |
Large Cap Stocks
32.81%
Mid Cap Stocks
28.07%
Small Cap Stocks
33.81%
AAA
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹1,110.39 Cr | 95.09% |
Financial Services | ₹15.48 Cr | 1.33% |
Basic Materials | ₹12.43 Cr | 1.06% |
Standard Deviation
This fund
15.96%
Cat. avg.
15.96%
Lower the better
Sharpe Ratio
This fund
0.78
Cat. avg.
0.79
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.44
Higher the better
Since May 2022
ISIN | INF789F01695 | Expense Ratio | 2.25% | Exit Load | 1.00% | Fund Size | ₹1,168 Cr | Age | 28 Jun 1999 | Lumpsum Minimum | ₹5,000 | Fund Status | Open Ended Investment Company | Benchmark | BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Dividends are added to the investor’s income and taxed according to their respective tax slabs. Additionally, if an investors dividend income exceeds INR 5,000 in a financial year, the fund house deducts a 10% Tax Deducted at Source (TDS) before distributing the dividend.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹14.97 Cr | 55.2% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹791.70 Cr | 56.3% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹791.70 Cr | 54.1% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹31.78 Cr | 52.5% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹183.39 Cr | 55.6% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹183.39 Cr | 52.7% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2560.38 Cr | 53.4% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2560.38 Cr | 51.2% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹798.61 Cr | 52.8% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹18.87 Cr | 51.4% |
Total AUM
₹3,15,582 Cr
Address
UTI Towers, Gn Block, Mumbai, 400 051
Your principal amount will be at Very High Risk